Both autologous and allogeneic anti-CD19 CAR T-cells have produced remission in previously treated patients with B-cell malignancies.[5,6] We describe 2 patients with Ph-positive ALL resistant to TKIs who underwent anti-CD19 CAR T-cell infusions. Here, CD19 is linked to acute lymphoblastic leukemia.